Sandoz invests USD 300 million in new biosimilar drug substance facility in Slovenia

PUBT · 1d ago
Sandoz invests USD 300 million in new biosimilar drug substance facility in Slovenia
  • Sandoz plans a new biosimilar drug-substance plant in Ljubljana, Slovenia, investing about USD 300 million.
  • Site targets startup in 2029, adding 8,000 liters of biologics capacity via four disposable fed-batch reactors.
  • Build-out expands in-house manufacturing for low- to medium-volume output, complementing existing high-volume, continuous production.
  • Project supports the Bio100 strategy, aiming to capture a larger share of the long-term biosimilars market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2395192_en) on September 08, 2026, and is solely responsible for the information contained therein.